journal
https://read.qxmd.com/read/33297724/targeting-viral-genome-synthesis-as-broad-spectrum-approach-against-rna-virus-infections
#21
REVIEW
Johanna Huchting
Zoonotic spillover, i.e. pathogen transmission from animal to human, has repeatedly introduced RNA viruses into the human population. In some cases, where these viruses were then efficiently transmitted between humans, they caused large disease outbreaks such as the 1918 flu pandemic or, more recently, outbreaks of Ebola and Coronavirus disease. These examples demonstrate that RNA viruses pose an immense burden on individual and public health with outbreaks threatening the economy and social cohesion within and across borders...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/33215505/real-world-single-center-experience-with-direct-acting-antivirals-for-improvement-of-the-liver-fibrosis-after-chronic-hepatitis-c-treatment
#22
JOURNAL ARTICLE
Sun Hee Lee, Hyun Phil Shin, Joung Il Lee
BACKGROUND: Recently, new direct-acting antivirals (DAAs) are known to eradicate chronic hepatitis C (CHC) virus infection and prevent the progression of liver fibrosis. Liver fibrosis may predispose to liver cirrhosis or hepatocellular carcinoma. We investigated the effect of DAAs on liver fibrosis using non-invasive methods, and evaluated the correlations of these methods. METHODS: We retrospectively analyzed 68 patients with CHC who were treated with DAAs and reached sustained virologic response at 12 weeks post-treatment from January 2016 to October 2018...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/33153278/small-molecule-antivirals-still-our-best-hope-for-a-cure
#23
EDITORIAL
Katherine Seley-Radtke
No abstract text is available yet for this article.
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32972196/clinical-evidences-on-the-antiviral-properties-of-macrolide-antibiotics-in-the-covid-19-era-and-beyond
#24
JOURNAL ARTICLE
Dimitri Poddighe, Mohamad Aljofan
Macrolides are a large group of antibiotics characterised by the presence of a macro-lactone ring of variable size. The prototype of macrolide antibiotics, erythromycin was first produced by Streptomyces and associated species more than half a century ago; other related drugs were developed. These drugs have been shown to have several pharmacological properties: in addition to their antibiotic activity, they possess some anti-inflammatory properties and have been also considered against non-bacterial infections...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32811155/spectrum-of-antiviral-activity-of-4-aminopyrimidine-n-oxides-against-a-broad-panel-of-tick-borne-encephalitis-virus-strains
#25
JOURNAL ARTICLE
Evgenia V Dueva, Ksenia K Tuchynskaya, Liubov I Kozlovskaya, Dmitry I Osolodkin, Kseniya N Sedenkova, Elena B Averina, Vladimir A Palyulin, Galina G Karganova
Tick-borne encephalitis is an important human arbovirus neuroinfection spread across the Northern Eurasia. Inhibitors of tick-borne encephalitis virus (TBEV) strain Absettarov, presumably targeting E protein n -octyl-β-d-glucoside (β-OG) pocket, were reported earlier. In this work, these inhibitors were tested in vitro against seven strains representing three main TBEV subtypes. The most potent compound, 2-[(2-methyl-1-oxido-5,6,7,8-tetrahydroquinazolin-4-yl)amino]-phenol, showed EC50 values lower than 22 µM against all the tested strains...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32741202/respiratory-syntycial-virus-current-treatment-strategies-and-vaccine-approaches
#26
JOURNAL ARTICLE
Elena Margret Thornhill, Jessica Salpor, David Verhoeven
Respiratory Syncytial Virus is a yearly respiratory virus that causes significant frequencies of morbidities, particularly in the young and elderly populations. However, preventive vaccines and/or treatment therapies are generally lacking, although much attention is now being placed on this virus. Moreover, there are now multiple strategies currently being explored in a race to the first licensed vaccine. While vaccines are being developed, multiple treatment strategies are being explored to attenuate the severity of infection and thus reduce hospitalization rates in vulnerable populations...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32434393/virologic-failure-after-48-weeks-of-raltegravir-based-regimen-in-low-hiv-1-incidence-setting
#27
JOURNAL ARTICLE
Wassim Chehadeh, Osama Albaksami, Shaikhah Al-Shammari
BACKGROUND: With the advent of next generation integrase strand transfer inhibitors, the rates of virologic failure in treated subjects are expected to decrease. In this study, we analyzed the mutation patterns leading to virologic failure before and after starting integrase strand transfer inhibitor-based regimen as first-line or salvage therapy. METHODS: Between 2016 and 2019, blood samples were received from 258 patients with HIV-1 infection. Plasma HIV-1 RNA concentrations, and pol gene sequences were determined at baseline, and 16-48 weeks of treatment with integrase strand transfer inhibitor-based regimen...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32418480/nucleos-t-ide-analogues-and-hepatitis-b-virus-related-hepatocellular-carcinoma-a-literature-review
#28
JOURNAL ARTICLE
Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso
Hepatitis B virus is mainly considered to cause hepatocellular carcinoma which is the fourth leading cause of cancer-related mortality worldwide. Treatment of Hepatitis B virus with nucleos(t)ide analogues can decrease the progression of the disease and subsequently decreases the incidence of hepatocellular carcinoma. In this review, we have discussed the different classes of nucleos(t)ide analogues used in the treatment of Hepatitis B virus and their relationship with the development of hepatocellular carcinoma...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32345035/application-of-human-lymphoid-cells-for-the-evaluation-of-antivirals-against-human-adenovirus-type-19-zalcitabine-has-superior-activity-compared-to-cidofovir
#29
JOURNAL ARTICLE
Kohsuke Nakagawara, Hironori Hayashi, Kumi Kawaji, Mina Sasano, Eiichi N Kodama
Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells)...
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32306749/in-vitro-anti-adenoviral-activities-of-ethanol-extract-fractions-and-main-phenolic-compounds-of-pomegranate-punica-granatum-l-peel
#30
JOURNAL ARTICLE
Ali Karimi, Mohammad-Taghi Moradi, Mohammad Rabiei, Somayeh Alidadi
No abstract text is available yet for this article.
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/32041425/genome-analysis-of-coxsackievirus-b1-isolates-during-the-consecutive-alternating-administration-course-of-triple-antiviral-combination-in-newborn-mice
#31
JOURNAL ARTICLE
Petar Grozdanov, Marie-Line Joffret, Adelina Stoyanova, Patsy Polston, Emna Achouri, Ivanka Nikolova, Francis Delpeyroux, Angel S Galabov
No abstract text is available yet for this article.
January 2020: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/31856576/incidence-of-cxcr4-tropism-and-ccr5-tropic-resistance-in-treatment-experienced-participants-receiving-maraviroc-in-the-48-week-motivate-1-and-2-trials
#32
JOURNAL ARTICLE
Becky Jubb, Marilyn Lewis, Lynn McFadyen, Paul Simpson, Julie Mori, Phylinda Chan, Barry Weatherley, Elna van der Ryst, Mike Westby, Charles Craig
No abstract text is available yet for this article.
January 2019: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/31744306/relevance-of-ebola-virus-vp35-homo-dimerization-on-the-type-i-interferon-cascade-inhibition
#33
JOURNAL ARTICLE
Francesco Di Palma, Gian Luca Daino, Venkata Krishnan Ramaswamy, Angela Corona, Aldo Frau, Elisa Fanunza, Attilio V Vargiu, Enzo Tramontano, Paolo Ruggerone
No abstract text is available yet for this article.
January 2019: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30788976/synthesis-and-anti-human-immunodeficiency-virus-activity-of-substituted-o-o-difluorophenyl-linked-pyrimidines-as-potent-non-nucleoside-reverse-transcriptase-inhibitors
#34
JOURNAL ARTICLE
Lucie Čechová, Milan Dejmek, Ondřej Baszczyňski, David Šaman, Liping Gao, Eric Hu, George Stepan, Petr Jansa, Zlatko Janeba, Petr Šimon
With the worldwide number of human immunodeficiency virus positive patients stagnant and the increasing emergence of viral strains resistant to current treatment, the development of novel anti-human immunodeficiency virus drug candidates is a perpetual quest of medicinal chemists. Herein, we report a novel group of diarylpyrimidines, non-nucleoside reverse transcriptase inhibitors, which represents an important class of current anti-human immunodeficiency virus therapy. Series of diarylpyrimidines containing o, o-difluorophenyl (A-arm), 4-cyanophenylamino (B-arm), and a small substituent (e...
January 2019: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30776910/mozobil%C3%A2-plerixafor-amd3100-10-years-after-its-approval-by-the-us-food-and-drug-administration
#35
REVIEW
Erik De Clercq
AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized the CD34+ stem cells from the bone marrow into the peripheral blood stream. In December 2008, AMD3100 was formally approved by the US FDA for autologous transplantation in patients with Non-Hodgkin's Lymphoma or multiple myeloma...
January 2019: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30759993/a-medium-throughput-screen-for-inhibitors-of-human-metapneumovirus
#36
JOURNAL ARTICLE
Jennifer C Becker, Sharon J Tollefson, David Weaver, John V Williams
Human metapneumovirus, a paramyxovirus discovered in 2001, is a major cause of lower respiratory infection in adults and children worldwide. There are no licensed vaccines or drugs for human metapneumovirus. We developed a fluorescent, cell-based medium-throughput screening assay for human metapneumovirus that captures inhibitors of all stages of the viral lifecycle except budding of progeny virus particles from the cell membrane. We optimized and validated the assay and performed a successful medium-throughput screening...
January 2019: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30497281/xanthine-based-acyclic-nucleoside-phosphonates-with-potent-antiviral-activity-against-varicella-zoster-virus-and-human-cytomegalovirus
#37
JOURNAL ARTICLE
Ondřej Baszczyňski, Martin Maxmilian Kaiser, Michal Česnek, Petra Břehová, Petr Jansa, Eliška Procházková, Martin Dračínský, Robert Snoeck, Graciela Andrei, Zlatko Janeba
While noncanonic xanthine nucleotides XMP/dXMP play an important role in balancing and maintaining intracellular purine nucleotide pool as well as in potential mutagenesis, surprisingly, acyclic nucleoside phosphonates bearing a xanthine nucleobase have not been studied so far for their antiviral properties. Herein, we report the synthesis of a series of xanthine-based acyclic nucleoside phosphonates and evaluation of their activity against a wide range of DNA and RNA viruses. Two acyclic nucleoside phosphonates within the series, namely 9-[2-(phosphonomethoxy)ethyl]xanthine (PMEX) and 9-[3-hydroxy-2-(phosphonomethoxy)propyl]xanthine (HPMPX), were shown to possess activity against several human herpesviruses...
January 2018: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30466301/activity-of-enisamium-an-isonicotinic-acid-derivative-against-influenza-viruses-in-differentiated-normal-human-bronchial-epithelial-cells
#38
JOURNAL ARTICLE
David Boltz, Xinjian Peng, Miguel Muzzio, Pradyot Dash, Paul G Thomas, Victor Margitich
AIMS: New therapeutics for the control of influenza virus infections are needed to alleviate the burden caused by seasonal epidemics and occasional pandemics, and to overcome the potential risk of drug-resistance emergence. Enisamium iodide (Amizon®, Farmak) is currently approved for clinical use for the treatment of influenza in 11 countries which includes Ukraine, Russia, Belarus, Kazakhstan, and Uzbekistan. However, experimental evidence of the antiviral activity of enisamium has not been reported...
January 2018: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30449131/cyclophilin-a-as-a-target-in-the-treatment-of-cytomegalovirus-infections
#39
JOURNAL ARTICLE
Ashwaq A Abdullah, Rasedee Abdullah, Zeenathul A Nazariah, Krishnan N Balakrishnan, Faez Firdaus J Abdullah, Jamilu A Bala, Mohd-Azmi Mohd-Lila
BACKGROUND: Viruses are obligate parasites that depend on the cellular machinery of the host to regenerate and manufacture their proteins. Most antiviral drugs on the market today target viral proteins. However, the more recent strategies involve targeting the host cell proteins or pathways that mediate viral replication. This new approach would be effective for most viruses while minimizing drug resistance and toxicity. METHODS: Cytomegalovirus replication, latency, and immune response are mediated by the intermediate early protein 2, the main protein that determines the effectiveness of drugs in cytomegalovirus inhibition...
January 2018: Antiviral Chemistry & Chemotherapy
https://read.qxmd.com/read/30354193/the-effectiveness-of-antiviral-agents-with-broad-spectrum-activity-against-chikungunya-virus-varies-between-host-cell-lines
#40
JOURNAL ARTICLE
Evelyn J Franco, Jaime L Rodriquez, Justin J Pomeroy, Kaley C Hanrahan, Ashley N Brown
Chikungunya virus (CHIKV) is a mosquito-borne virus that has recently emerged in the Western Hemisphere. Approved antiviral therapies or vaccines for the treatment or prevention of CHIKV infections are not available. This study aims to evaluate the antiviral activity of commercially available broad-spectrum antivirals against CHIKV. Due to host cell-specific variability in uptake and intracellular processing of drug, we evaluated the antiviral effects of each agent in three cell lines. Antiviral activities of ribavirin (RBV), interferon-alfa (IFN-α) and favipiravir (FAV) were assessed in CHIKV-infected Vero, HUH-7, and A549 cells...
January 2018: Antiviral Chemistry & Chemotherapy
journal
journal
30471
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.